A novel matrix metalloproteinase-2 inhibitor triazolylmethyl aziridine reduces melanoma cell invasion, angiogenesis and targets ERK1/2 phosphorylation

References

• Kahari VM, Saarialho-Kere U. Matrix metalloproteinases and their inhibitors in tumour growth and invasion. Ann Med 1999;31:34–45. [PubMed: 10219712]
   PubMed Web of Science ®Google Scholar
• Kleiner DE, Stetler-Stevenson WG. Matrix metalloproteinases and metastasis. Cancer Chemother Pharmacol 1999;43:S42–51. [PubMed: 10357558]
   PubMed Web of Science ®Google Scholar
• Denis LJ, Verweij J. Matrix metalloproteinase inhibitors: present achievements and future prospects. Invest New Drugs 1997;15:175–85. [PubMed: 11448904]
   PubMed Web of Science ®Google Scholar
• Wojtowicz-Praga SM, Dickson RB, Hawkins MJ. Matrix metalloproteinase inhibitors. Invest New Drugs 1997;15:61–75. [PubMed: 9195290]
   PubMed Web of Science ®Google Scholar
• Hanemaaijer R. Verheijen JH, Maguire TM, et al. Increased gelatinase-A and gelatinase-B activitiesin malignant vs. benign breast tumors. Int J Cancer 2000;86:204–7. [PubMed: 10738247]
   PubMed Web of Science ®Google Scholar
• Pellikainen JM, Ropponen KM, Kataja VV, et al. Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis. Clin Cancer Res 2004;10:7621–28. [PubMed: 15569994]
   PubMed Web of Science ®Google Scholar
• Wilson CL, Heppner KJ, Labosky PA, et al. Intestinal tumorigenesis is suppressed in mice lacking the metalloproteinase matrilysin. Proc Natl Acad Sci USA 1997;94:1402–7. [PubMed: 9037065]
   PubMed Web of Science ®Google Scholar
• Fingleton BM, Heppner Goss KJ, Crawford HC, Matrisian LM. Matrilysin in early stage intestinal tumorigenesis. APMIS 1999;107:102–10. [PubMed: 10190286]
   PubMed Web of Science ®Google Scholar
• Zhou L, Wang D-S, Li Q-J, et al. Downregulation of the Notch signaling pathway inhibits hepatocellular carcinoma cell invasion by inactivation of matrix metalloproteinase-2 and -9 and vascular endothelial growth factor. Oncol Rep 2012;28:874–82. [PubMed: 22736202]
   PubMed Web of Science ®Google Scholar
• Yarani R, Mansouri K, Mohammadi-Motlagh HR, et al. In vitro inhibition of angiogenesis by hydroalcoholic extract of oak (Quercus infectoria) acorn shell via suppressing VEGF, MMP-2, and MMP-9 secretion. Pharm Biol 2013;51:361–8. [PubMed: 23137183]
   PubMed Web of Science ®Google Scholar
• Brand K, Baker AH, Perez-Canto A, et al. Treatment of colorectal liver metastases by adenoviral transfer of tissue inhibitor of metalloproteinases-2 into the liver tissue. Cancer Res 2000;60:5723–30. [PubMed: 11059766]
   PubMed Web of Science ®Google Scholar
• Nemeth JA, Yousif R, Herzog M, et al. Matrix metalloproteinase activity, bone matrix turnover, and tumor cell proliferation in prostate cancer bone metastasis. J Natl Cancer Inst 2002;94:17–25. [PubMed: 11773278]
   PubMed Web of Science ®Google Scholar
• Stockman BJ, Waldon DJ, Gates JA, et al. Solution structures of stromelysin complexed to thiadiazole inhibitors. Protein Sci 1998;7:2281–6. [PubMed: 9827994]
   PubMed Web of Science ®Google Scholar
• Igarashi N, Kubota T, Otani Y, et al. Preventive effect of matrix metalloproteinase inhibitor, R-94138, in combination with mitomycin C or cisplatin on peritoneal dissemination of human gastric cancer cell line TMK-1 in nude mice. Jpn J Cancer Res 1999;90:116–21. [PubMed: 10076574]
   PubMedGoogle Scholar
• Kido A, Tsutsumi M, Iki K, et al. Inhibition of spontaneous rat osteosarcoma lung metastasis by 3S-[4-(N-hydroxyamino)-2R-isobutylsuccinyl]amino-1-methoxy-3,4-dihydroc arbostyril, a novel matrix metalloproteinase inhibitor. Jpn J Cancer Res 1999;90:333–41. [PubMed: 10359049]
   PubMedGoogle Scholar
• Lozonschi L, Sunamura M, Kobari M, et al. Controlling tumor angiogenesis and metastasis of C26 murine colon adenocarcinoma by a new matrix metalloproteinase inhibitor, KB-R7785, in two tumor models. Cancer Res 1999;59:1252–8. [PubMed: 10096556]
   PubMed Web of Science ®Google Scholar
• Chen P-S, Shih Y-W, Huang H-C, Cheng H-W. Diosgenin, a steroidal saponin, inhibits migration and invasion of human prostate cancer PC-3 cells by reducing matrix metalloproteinases expression. PLoS One 2011;6:e20164. [PubMed: 21629786]
   PubMed Web of Science ®Google Scholar
• Hanessian S, Tremblay M, Kornienko A, Moitessier N. Design, modeling and synthesis of functionalized paromamine analogs. Tetrahedron 2001;57:3255–65
   Web of Science ®Google Scholar
• Zapico JM, Serra P, García-Sanmartín J, et al. Potent “clicked” MMP-2 inhibitors: synthesis, molecular modeling and biological exploration. Org Biomol Chem 2011;9:4587–99. [PubMed: 21552627]
   PubMed Web of Science ®Google Scholar
• Serra P, Bruczko M, Zapico JM, et al. MMP-2 selectivity in hydroxamate-type inhibitors. Curr Med Chem 2012;19:1036–64. [PubMed: 22257051]
   PubMed Web of Science ®Google Scholar
• Nicolotti O, Miscioscia TF, Leonetti F, et al. Screening of matrix metalloproteinases available from the protein data bank: insights into biological functions, domain organization, and zinc binding groups. J Chem Inf Model 2007;47:2439–48. [PubMed: 17958346]
   PubMed Web of Science ®Google Scholar
• Testero SA, Llarrull LI, Fisher JF, et al. Exploring the functional space of thiiranes as gelatinase inhibitors using click chemistry. ARKIVOC 2011;7:221–36
   Google Scholar
• Amadasi A, Cozzini P, Incerti M, et al. Molecular modeling of bindingbetween amidinobenzisothiazoles, with antidegenerative activity on cartilage, and matrix metalloproteinase-3. Bioorg Med Chem 2007;15:1420–9. [PubMed: 17113299]
   PubMed Web of Science ®Google Scholar
• Engel CK, Pirard B, Schimanski S, et al. Structural basis for the highly selective inhibition of MMP-13. Chem Biol 2005;12:181–9. [PubMed: 15734645]
   PubMed Web of Science ®Google Scholar
• Tron GC, Pirali T, Billington RA, et al. Click chemistry reactions in medicinal chemistry: applications of the 1,3-dipolar cycloaddition between azides and alkynes. Med Chem Rev 2008;28:278–308
   Google Scholar
• Hayashi R, Jin X, Cook GR. Synthesis and evaluation of novel heterocyclic MMP inhibitors. Bioorg Med Chem Lett 2007;17:6864–70. [PubMed: 7763363]
   PubMedGoogle Scholar
• Hugenberg V, Breyholz H-J, Riemann B, et al. A new class of highly potent matrix metalloproteinase inhibitors based on triazole-substituted hydroxamates: (radio)synthesis and in vitro and first in vivo evaluation. J Med Chem 2012;55:4714–27. [PubMed: 22540974]
   PubMed Web of Science ®Google Scholar
• Saotome K, Morita H, Umeda M. Cytotoxicity test with simplified crystal violet staining method using microtitre plates and its application to injection drugs. Toxicol in vitro 1989;3:317–21. [PubMed: 20702298]
   PubMed Web of Science ®Google Scholar
• Twentyman PR, Luscombe M. A study of some variables in a tetrazolium dye (MTT) based assay for cell growth and chemosensitivity. Br J Cancer 1987;56:279–85. [PubMed: 3663476]
   PubMed Web of Science ®Google Scholar
• Kreituss I, Rozenberga E, Zemitis J, et al. Discovery of aziridine-triazole conjugates as selective MMP-2 inhibitors. Chem Heterocycl Comp. 2013;8:1191–200. DOI: 10.1039/c2cc36225b
   Google Scholar
• Trapencieris P, Kalviņš I, Kauliņa L, Kauss V. Unnatural amino acids. 1. A facile synthesis of the methyl ester of aziridine-2-carboxylic acid. Org Process Res Dev 1997;1:259–63
   Web of Science ®Google Scholar
• Jamookeeah CE, Beadle CD, Jackson RFW, Harrity JPA. Investigation of a flexible enantiospecific approach to aziridines. J Org Chem 2008;73:1128–30. [PubMed: 18179238]
   PubMed Web of Science ®Google Scholar
• Jamookeeah CE, Beadle CD, Harrity JPA. An enantiospecific approach to triazolylalanine derivatives. Synthesis 2009;1:133–7. DOI: 10.1055/s-0028-1083270
   Google Scholar
• Hofmann UB, Westphal JR, Waas ET, et al. Matrix metalloproteinases in human melanoma cell lines and xenografts: increased expression of activated matrix metalloproteinase-2 (MMP-2) correlates with melanoma progression. Br J Cancer 1999;81:77–82. [PubMed: 10555745]
   Web of Science ®Google Scholar
• Berube M, Deschambeault A, Boucher M, et al. MMP-2 expression in uveal melanoma: differential activation status dictated by the cellular environment. Mol/Vis 2005;11:1101–11. [PubMed: 16379022]
   Google Scholar
• Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature 1993;362:841–4. [PubMed: 7683111]
   PubMed Web of Science ®Google Scholar
• Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002;2:161–74. [PubMed: 11990853]
   PubMed Web of Science ®Google Scholar
• Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004;25:581–611. [PubMed: 15294883]
   PubMed Web of Science ®Google Scholar
• Löffek S, Zigrino P, Steiger J, et al. Melanoma cell-derived vascular endothelial growth factor induces endothelial tubulogenesis within fibrin gels by a metalloproteinase-mediated mechanism. Eur J Cell Biol 2006;85:1167–77. [PubMed: 16949178]
   PubMed Web of Science ®Google Scholar
• Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000;407:249–57. [PubMed: 11001068]
   PubMed Web of Science ®Google Scholar
• Zhang G, Dass CR, Sumithran E, et al. Effect of deoxyribozymes targeting c-Jun on solid tumor growth and angiogenesis in rodents. J Natl Cancer Inst 2004;96:683–96. [PubMed: 5126605]
   PubMed Web of Science ®Google Scholar
• Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 2010;141:52–67. [PubMed: 20371345]
   PubMed Web of Science ®Google Scholar
• Chambers AF, Matrisian LM. Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 1997;89:1260–70. [PubMed: 9293916]
   PubMed Web of Science ®Google Scholar
• Duffy MJ, Maguire TM, Hill A, et al. Metalloproteinases: role in breast carcinogenesis, invasion and metastasis. Breast Cancer Res 2000;2:252–7. [PubMed: 11250717]
   PubMed Web of Science ®Google Scholar
• Yoon S-O, Park S-J, Yun C-H, Chung A-S. Roles of matrix metalloproteinases in tumor metastasis and angiogenesis. J Biochem Mol Biol 2003;36:128–37. [PubMed: 12542983]
   PubMedGoogle Scholar
• Panek RL, Lu GH, Klutchko SR, et al. In vitro pharmacological characterization of PD 166285, a new nanomolar potent and broadly active protein tyrosine kinase inhibitor. J Pharmacol Exp Ther 1997;283:1433–44. [PubMed: 9400019]
   PubMed Web of Science ®Google Scholar
• Ferguson J, Arozarena I, Ehrhardt M, Wellbrock M. combination of MEK and SRC inhibition suppresses melanoma cell growth and invasion. Oncogene 2012;32:86–96. [PubMed: 22310287]
   PubMed Web of Science ®Google Scholar
• Skiles JW, Gonnella NC, Jeng AY. The design, structure, and therapeutic application of matrix metalloproteinase inhibitors. Curr Med Chem 2001;8:425–74. [PubMed: 11172697]
   PubMed Web of Science ®Google Scholar
• Testero SA, Bouley R, Fisher JF, et al. Exploration of mild copper-mediated coupling of organotrifluoroborates in the synthesis of thiirane-based inhibitors of matrix metalloproteinases. Bioorg Med Chem Lett 2011;21:2675–8. [PubMed: 21256011]
   PubMed Web of Science ®Google Scholar
• Overall CM, Kleifeld O. Towards third generation matrix metalloproteinase inhibitors for cancer therapy. Br J Cancer 2006;94:941–6. [PubMed: 16538215]
   PubMed Web of Science ®Google Scholar
• Hidalgo M, Eckhardt SG. Development of matrix metalloproteinase inhibitors in cancer therapy. J Natl Cancer Inst 2001;93:178–93. [PubMed: 11158186]
   PubMed Web of Science ®Google Scholar
• Ray JM, Stetler-Stevenson WG. Gelatinase A activity directly modulates melanoma cell adhesion and spreading. EMBO J 1995;14:90–7. [PubMed: 7534227]
   Web of Science ®Google Scholar
• Giannelli G, Falk-Marzillier J, schiraldi O, et al. Induction of cell migration by matrix metalloproteinase-2 cleavage of laminin-5. Science 1997;277:225–8. [PubMed: 9211848]
   PubMed Web of Science ®Google Scholar
• Kubota Y. Tumor angiogenesis and anti-angiogenic therapy. Keio J Med 2012;61:47–56. [PubMed: 22760023]
   PubMedGoogle Scholar
• Ferrara N. VEGF-A: a critical regulator of blood vessel growth. Eur Cytokine Netw 2009;20:158–63. [PubMed: 20167554]
   PubMed Web of Science ®Google Scholar
• Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature 2005;438:967–74. [PubMed: 16355214]
   PubMed Web of Science ®Google Scholar
• Mackay AR, Corbitt RH, Hartzler JL, Thorgeirsson UP. Basement membrane type IV collagen degradation: evidence for the involvement of a proteolytic cascade independent of metalloproteinases. Cancer Res 1990;50:5997–6001. [PubMed: 2144209]
   PubMed Web of Science ®Google Scholar
• Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM. Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol 2000;18:1135–49. [PubMed: 10694567]
   PubMed Web of Science ®Google Scholar
• Liabakk NB, Talbot I, Smith RA, et al. Matrix metalloprotease 2 (MMP-2) and matrix metalloprotease 9 (MMP-9) type IV collagenases in colorectal cancer. Cancer Res 1996;56:190–6. [PubMed: 8548762]
   PubMed Web of Science ®Google Scholar
• Johnsen M, Lund LR, Romer J, et al. Cancer invasion and tissue remodeling: common themes in proteolytic matrix degradation. Curr Opin Cell Biol 1998;10:667–71. [PubMed: 9818179]
   PubMed Web of Science ®Google Scholar
• Beshir AB, Ren G, Magpusao AN, et al. Raf kinase inhibitor protein suppresses nuclear factor-κB dependent cancer cell invasion through negative regulation of matrix metalloproteinase expression. Cancer Lett 2010;299:137–49. [PubMed: 20855151]
   PubMed Web of Science ®Google Scholar
• Westermarck J, Kahari VM. Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J 1999;13:781–92. [PubMed: 10224222]
   PubMed Web of Science ®Google Scholar
• Chen P-N, Hsieh Y-S, Chiou H-L, Chu S-C. Silibinin inhibits cell invasion through inactivationof both PI3K-Akt and MAPK signaling pathways. Chem Biol Interact 2005;156:141–50. [PubMed: 16498067]
   PubMed Web of Science ®Google Scholar
• Holmes K, Roberts OL, Thomas AM, Cross MJ. Vascular endothelial growth factor receptor-2: structure, function, intracellular signaling and therapeutic inhibition. Cell Signal 2007;19:2003–12. [PubMed: 17658244]
   PubMed Web of Science ®Google Scholar
• Simon C, Juarez J, Nicolson GL, Boyd D. Effect of PD 098059, a specific inhibitor of mitogen-activated protein kinase, on urokinase expression and in vitro invasion. Cancer Res 1996;56:5369–74. [PubMed: 8968087]
   PubMed Web of Science ®Google Scholar
• Simon C, Goepfert H, Boyd D. Inhibition of the p38 mitogen-activated protein kinase by SB 203580 blocks PMA-induced Mr 92,000 type IV collagenase secretion and in vitro invasion. Cancer Res 1998;58:1135–9. [PubMed: 9515796]
   PubMed Web of Science ®Google Scholar
• Graells J, Vinyals A, Figueras A, et al. Overproduction of VEGF concomitantly expressed with its receptors promotes growth and survival of melanoma cells through MAPK and PI3K signaling. J Invest Dermatol 2004;123:1151–61. [PubMed: 15610528]
   PubMed Web of Science ®Google Scholar
• Siveen KS, Kuttan G. Thujone inhibits lung metastasis induced by B16F-10 melanoma cells in C57BL/6 mice. Can J Physiol Pharmacol 2011;89:691–703. [PubMed: 21905822]
   PubMed Web of Science ®Google Scholar